Company news

Adaptive Biotechnologies Corporation news in 2020

Adaptive Biotechnologies Corporation's news releases, calls and decks from 2020, newest first.

View company

Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference

December 29, 2020

Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting

December 5, 2020

Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients

November 22, 2020

Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections

November 12, 2020

Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results

November 9, 2020

Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio

November 9, 2020

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020

October 12, 2020

Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference

August 31, 2020

Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit

August 9, 2020

Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results

August 9, 2020

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia

August 5, 2020

Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2

August 3, 2020

Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease

July 27, 2020

Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock

July 14, 2020

Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock

July 13, 2020

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020

July 8, 2020

UPDATE – Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

June 7, 2020

Adaptive Biotechnologies Reports First Quarter 2020 Financial Results

May 11, 2020

Adaptive Biotechnologies to Present at the BofA Securities 2020 Healthcare Conference

May 5, 2020

Adaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020

April 26, 2020

Adaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx

April 8, 2020

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2019 Financial Results

February 25, 2020

Adaptive Biotechnologies to Present at the 40th Annual Cowen Health Care Conference

February 18, 2020

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020

February 11, 2020

Adaptive Announces Pricing of Public Offering of Common Stock

January 22, 2020

Adaptive Announces Proposed Public Offering of Common Stock

January 20, 2020

Adaptive Announces Preliminary Unaudited Revenue for Full Year 2019

January 20, 2020

Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients

January 12, 2020

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia

January 7, 2020

Calls in 2020

Decks in 2020